Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.44 |
| ▸ | GRK2 | P25098 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30218733 | 1.00 | LMNA (0.68) | LMNATDP1CYP19A1HTTALDH1A1 | |
| SCHEMBL30302069 | 0.85 | SRC (0.47) | LMNATDP1ALDH1A1SMN1; SMN2SRC | |
| SCHEMBL2537809 | 0.85 | SRC (0.47) | LMNATDP1ALDH1A1SMN1; SMN2SRC | |
| SCHEMBL30631693 | 0.84 | SRC (0.60) | LMNATDP1ALDH1A1SMN1; SMN2SRC | |
| SCHEMBL6849018 | 0.84 | SRC (0.60) | LMNATDP1ALDH1A1SMN1; SMN2SRC | |
| SCHEMBL25491407 | 0.83 | LMNA (0.68) | LMNATDP1CYP19A1HTTALDH1A1 | |
| SCHEMBL31238435 | 0.83 | KDM4E (0.58) | LMNATDP1CYP19A1HTTALDH1A1 | |
| SCHEMBL30622718 | 0.83 | SMN1; SMN2 (0.50) | LMNATDP1ALDH1A1SMN1; SMN2SRC | |
| SCHEMBL433465 | 0.83 | KDM4E (0.58) | LMNATDP1CYP19A1HTTALDH1A1 | |
| SCHEMBL2533132 | 0.83 | SMN1; SMN2 (0.50) | LMNATDP1ALDH1A1SMN1; SMN2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258340-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2025-03-25 | — | — | US | disclosed |
| CN-117567450-A | Oxazolone compound, pharmaceutical composition and application thereof | 中国药科大学 | 2024-02-20 | — | — | CN | disclosed |
| CN-116473965-A | Pyrazole MAGL inhibitors | H.隆德贝克有限公司 | 2023-07-25 | — | — | CN | disclosed |
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2023-07-13 | — | — | US | disclosed |
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2023-07-13 | — | — | US | disclosed |
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2023-07-13 | — | — | US | disclosed |
| EP-4198024-A1 | PYRAZOLE MAGL INHIBITORS | H. Lundbeck A/S (DK) | 2023-06-21 | — | — | EP | disclosed |
| EP-4198024-A1 | PYRAZOLE MAGL INHIBITORS | H. Lundbeck A/S (DK) | 2023-06-21 | — | — | EP | disclosed |
| US-11655217-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2023-05-23 | — | — | US | disclosed |
| US-11655217-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2023-05-23 | — | — | US | disclosed |
| US-20150266862-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-8044090-B2 | N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor | ELI LILLY (US) | 2011-10-25 | — | — | US | disclosed |
| US-20090306110-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | CHEN ZHAOGEN | 2009-12-10 | — | — | US | disclosed |
| EP-1859798-A1 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2007-11-28 | — | — | EP | disclosed |
| EP-1379239-B1 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | LILLY CO ELI (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070099909-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | CHEN ZHAOGEN | 2007-05-03 | — | — | US | disclosed |
| US-7157488-B2 | N-(2-Arylethyl) benzylamines as antagonists of the 5-HT6 receptor | ELI LILLY AND COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | CHEN ZHAOGEN | 2006-01-12 | — | — | US | disclosed |
| EP-1379239-A2 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002078693-A2 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | MGLL, PNLIP, LPL | LMNA 2986/4885TDP1 2067/4885CYP19A1 1342/4885 |
| US-12258340-B2 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | LMNA 3058/4885TDP1 1754/4885CYP19A1 1432/4885 |
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | HTR6, HTR2C, HTR1B | LMNA 4040/4885TDP1 4272/4885CYP19A1 1849/4885 |
| US-20090306110-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | HTR6, HTR2C, HTR1B | LMNA 4040/4885TDP1 4272/4885CYP19A1 1849/4885 |
| US-20150266862-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | CACNA1B, CACNG6, SCN5A | LMNA 968/4885TDP1 2604/4885CYP19A1 4299/4885 |
| US-11655217-B2 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | LMNA 3058/4885TDP1 1754/4885CYP19A1 1432/4885 |
| US-20070099909-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | HTR6, HTR2C, HTR1B | LMNA 4040/4885TDP1 4272/4885CYP19A1 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.